Privately-held German firm Immatics Biotechnologies has entered into a research collaboration and license… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (generics, biosimilars, coronavirus/COVID-19, digital pharma, Asia Pacific), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.
Germany's Immatics Biotechnologies has signed a licensing agreement with Danish biotech firm Genmab. They'll combine their technologies to develop several T cell-engaging bispecific immunotherapies against cancer. Under the financial terms of the deal, Immatics will get a $54m initial fee, up to $550m in "milestone" payments and tiered royalties on product sales. Genmab has the option to expand the partnership if it is economically viable.